The Westin Copley Place, Boston, 10 Huntington Avenue,

Boston,

MA,

USA,

ZIP: 02116

Phone: +1 617 455 4188

As landmark Ferring and Seres Therapeutics approvals prove the safety of the microbiome modality, robust clinical efficacy data for disease beyond infectious is now paramount to reinvigorate investment across the community.

The 9th Microbiome Movement Drug Development Summit returns as the industry's trusted, definitive forum for the global network of microbial therapeutic developers. It ensures teams can stay ahead of the curve to robustly prove clinical efficacy as regulator and investor scrutiny necessitates more compelling data than ever before.

Your only meeting dedicated to supporting business-critical networking, featuring a start-up showcase to connect the ecosystem, this is an unmissable touchpoint for developers to gain insights from pipelines generating robust data in the clinic and improve your navigation of a fast-evolving market landscape.

Across 2 conference days, with Translational, Clinical and Manufacturing tracks, and an additional 4 deep-dive workshops and a Focus Day designed for innovation scouting and networking, join C-Level and Investor stakeholders, as 250+ innovators and thought-leaders gather under the common goal to prove the power of microbiome modalities!

Be part of the industry's premier platform for connection-building in 2024 and shape the future direction of the microbiome-altering therapeutics field!

URLs:
Tickets: https://go.evvnt.com/2317343-2?pid=1052
Brochure: https://go.evvnt.com/2317343-3?pid=1052

Prices:
Drug Developer Pricing - Conference + Focus Day : USD 4946.00,
Drug Developer Pricing - Conference + Workshop Day: USD 4946.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Start-Up Pricing - Conference + Focus Day: USD 3946.00,
Start-Up Pricing - Conference + Workshop Day: USD 3946.00,
Start-Up Pricing - Conference Only: USD 2199.00,
Solution Provider - Conference + Focus Day: USD 6246.00,
Solution Provider - Conference + Workshop Day: USD 6246.00,
Solution Provider - Conference Only: USD 4099.00

Ada Lam, Research Analyst, Beacon Microbiome, Adam Harvey, Associate Director - Clinical Research, Global Clinical and Translational Sciences, Ferring Pharmaceuticals, Adam Wilkinson, Vice President - Pre-Clinical Development, Microbiotica, Amir Zarrinpar, Founder and Chief Medical Officer, Endure Bio, Andrew Bartko, Executive Director for the Center of Microbiome Innovation, UC San Diego, Becca Senter, Vice President, Head of Preclinical RandD, Axial Therapeutics, Bernardo Cervantes, Chief Operating Officer and Co-Founder, Concerto Biosciences, Caitlin Hall, Head of Research, Myota Health, Caleb Bell, Venture Partner, Conundrum Systems Biology, Chris McChalicher, Vice President, CMC Technical Development, Seres Therapeutics, Chrysi Sergaki, Microbiome Group Leader, MHRA, Claire Derlot, Chief Business Officer, Biose Industrie, Colleen Acosta, Chief Executive Officer, Freya Biosciences, Dan Brownell, Head of Research and Development, AOBiome, Daniel van der Lelie, Chief Executive Officer and Chief Scientific Officer, Gusto Global, Denise Kelly, Investment Advisor, Seventure Partners, Dylan Lawrence, Research Scientist, Washington University in St. Louis, Pfizer, Elran Haber, Chief Executive Officer, Biomica, Evelina Vagesjo, Chief Executive Officer, Ilya, Gary Fanger, Chief Executive Officer, Rise Therapeutics, Giulio Maria Pasinetti, The Saunders Family Chair and Professor of Neurology, Psychiatry, Neuroscience, Geriatrics and Adult Development, Icahn School of Medicine at Mount Sinai, Greg Medlock, Director - Research, Vedanta Biosciences, Herve Affagard, Chief Executive Officer, Maat Pharma, Hiroto Tamura, Director of Business Management Division, Metagen Therapeutics, James Morton, Consultant, Simons Foundation, Jun Terauchi, Chief Scientific Officer, Metagen Therapeutics, Katy Patras, Assistant Professor, Baylor College of Medicine, Ken Blount, Chief Scientific Officer, Rebiotix, A Ferring Company, Koji Yasuda, Principal, Life Science Venture Capitalist, Fast Track Initiative, Kolby Day, Chief Operating Officer, BiomeBank, Marc Tewey, Chief Executive Officer, Exegi Pharmaceuticals, Mariia Taguer, Scientist, Microbiology and Bioengineering, Merck and Co, Nadim Ajami, Executive Director, Scientific Research, Platform for Innovative Microbiome and Translational Research (PRIME-TR), MD Anderson Cancer Center, Nikole Kimes, Founder and Chief Executive Officer, Siolta Therapeutics, Olaf Larsen, Senior Manager Science and Management Team and Professor , One Health Innovation, Athena Institute, Yakult Netherlands and Vrije Universiteit Amsterdam, Richard Day, Vice President Medical Affairs and Clinical Development, ADM, Robert Brucker, Co-Founder and Chief Scientific Officer, DermBiont, Robert Mills, Scientific Director, Piton Therapeutics, Sam Possemiers, Chief Executive Officer, MRM Health, Silvia Caballero, Program Officer, Microbiome Products, Bill and Melinda Gates Foundation, Vanesa Natalin, Rocha Martin Chief Executive Officer, SURI BioTech